Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 13/20 | 0.64 |
| ▸ | PPARG | P37231 | 6/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | FABP2 | P12104 | 2/20 | 0.56 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.53 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27849569 | 0.87 | PPARA (0.64) | PPARAPPARGCYP1A2CYP3A4MEN1 | |
| SCHEMBL3500736 | 0.87 | PPARA (0.68) | PPARAPPARGCYP1A2CYP3A4MEN1 | |
| SCHEMBL11548438 | 0.87 | ADORA3 (0.48) | PPARAPPARGCYP1A2CYP3A4MEN1 | |
| SCHEMBL5531801 | 0.85 | ADORA3 (0.47) | PPARAPPARGCYP1A2CYP3A4MEN1 | |
| SCHEMBL8935937 | 0.85 | PPARG (0.53) | PPARAPPARGCYP1A2CYP3A4MEN1 | |
| SCHEMBL82055 | 0.85 | PPARG (0.53) | PPARAPPARGCYP1A2CYP3A4MEN1 | |
| SCHEMBL2560059 | 0.84 | L3MBTL1 (0.50) | PPARAPPARGCYP1A2CYP3A4MEN1 | |
| SCHEMBL4852302 | 0.84 | PPARA (0.49) | PPARAPPARGCYP1A2CYP3A4MEN1 | |
| SCHEMBL16753083 | 0.84 | ADORA3 (0.46) | PPARAPPARGCYP1A2CYP3A4MEN1 | |
| SCHEMBL2557598 | 0.81 | ADORA3 (0.44) | PPARAPPARGCYP1A2CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807138-B2 | Biomarkers of metabolic responses to hepatic drugs | METABOLON, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20080213745-A1 | Biomarkers Of Metabolic Responses To Hepatotoxicants And Carcinogens | METABOLON, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080176266-A1 | Biomarkers Of Metabolic Responses To Hepatotoxicants And Carcinogens | METABOLON, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080058373-A1 | Compositions and Methods for Treating or Preventing Glaucoma or Progression Thereof | VRX HOLDCO LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1173165-A4 | CARDIOVASCULAR AND BONE TREATMENT USING ISOFLAVONES | NOVOGEN RES PTY LTD (AU) | 2004-05-12 | — | — | EP | disclosed |
| US-20040072765-A1 | Cardiovascular and bone treatment using isoflavones | NOVOGEN RESEARCH PTY LTD. | 2004-04-15 | — | — | US | disclosed |
| EP-1173165-A1 | CARDIOVASCULAR AND BONE TREATMENT USING ISOFLAVONES | Novogen Research Pty. Ltd. (AU) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064438-A1 | CARDIOVASCULAR AND BONE TREATMENT USING ISOFLAVONES | NOVOGEN RESEARCH PTY LTD (AU) | 2000-11-02 | — | — | WO | disclosed |
| EP-0261439-B1 | MEDICAMENT FOR CURING ARTERIOSCLEROSIS, COMPRISING PYRIMIDO (2,1-B) BENZOTHIAZOLE DERIVATIVE | MECT CORPORATION (JP) | 1991-09-04 | — | — | EP | disclosed |
| EP-0261439-A2 | Medicament for curing arteriosclerosis, comprising pyrimido (2,1-b) benzothiazole derivative | MECT CORPORATION (JP) | 1988-03-30 | — | — | EP | disclosed |
| US-4318923-A | HYPOLIPEMIC AGENT | KAKEN CHEMICAL CO., LTD. (JP) | 1982-03-09 | — | — | US | disclosed |
| US-4278678-A | ANTILIPEMIC AGENTS | KAKEN CHEMICAL CO., LTD. (JP) | 1981-07-14 | — | — | US | disclosed |
| US-4153724-A | Benzoyl phenoxy acetic acid derivatives | KAKEN CHEMICAL CO., LTD. (JP) | 1979-05-08 | — | — | US | disclosed |
| US-4119633-A | HYPOLIPEMIC, HYPOCHOLESTRIC AGENTS | CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1978-10-10 | — | — | US | disclosed |
| US-4082913-A | ANTI-ATHEROSCLEROSIS | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-04-04 | — | — | US | disclosed |
| US-3995061-A | AN ASCOCHLORIN DERIVATIVE USED IN THE TREATMENT OF ARTERIOSCLEROSIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JA) | 1976-11-30 | — | — | US | disclosed |
| US-3985790-A | ANTILIPEMIC AND ANTICHOLESTEREMIC AGENTS | LUDWIG MERCKLE KG (DT) | 1976-10-12 | — | — | US | disclosed |
| US-3984413-A | ANTILIPEMIC, ANTICHOLESTEROLEMIC; PERIPHERAL AND VASOLIDATIVE EFFECT | L. MERCKLE KG (DT) | 1976-10-05 | — | — | US | disclosed |
| US-3979405-A | HYPOLIPEMIC AND HYPOCHOLESTERIC AGENTS | GYOGYSZER- ES VEGYESZETI TERMEKEK GYARA RT. (HU) | 1976-09-07 | — | — | US | disclosed |
| US-3970694-A | ANTICHOLESTEROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058373-A1 | Compositions and Methods for Treating or Preventing Glaucoma or Progression Thereof | PTGIR, PTGDR, NR3C1 | PPARA 358/4885PPARG 65/4885CYP1A2 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.